Evidence-labeled research on peptide-based treatments in Type 1 diabetes — from approved therapies like insulin and pramlintide, through GLP-1 adjunct research and peptide immunotherapy, to honest coverage of unregulated research peptides sold online. Information, not medical advice.
Newest public articles in this topic cluster.
Highest growth-index pieces and decision-engine promote picks — still evidence-labeled, not medical advice.
Scientists have identified unusual peptide combinations that appear to drive autoimmune attack in Type 1 diabetes. Early research suggests these hybrid insulin peptides might be used to train the immune system to tolerate beta cells.
Amylin is a natural hormone that helps regulate blood sugar. After decades as a lesser-known treatment, new research is expanding how it might help people with diabetes and related conditions.
Researchers have been studying GLP-1 receptor agonists as an add-on treatment for Type 1 diabetes. Here's what early trials revealed—and how the approach is evolving.
Scientists developed nanoparticles that target liver cells to help the immune system tolerate insulin-producing cells instead of attacking them. In animal models, this approach reduced diabetes development.
Research shows that four weeks of regular exercise before pancreatic islet transplantation may help recipients achieve better blood sugar control after surgery. The findings highlight a potential low-cost way to prepare the body for transplant.
Amylin is a hormone your body normally makes alongside insulin. Research shows that adding an amylin-like medication to insulin therapy may help improve blood sugar control in Type 1 diabetes.
Researchers are investigating whether adding two types of glucose-lowering medications to insulin therapy could help people with Type 1 diabetes achieve better blood sugar control. These drugs are not yet FDA-approved for Type 1 diabetes, but doctors are using them off-label in some cases.
A new study suggests that frequent dried blood spot sampling may better detect early signs of beta cell preservation than traditional testing methods, offering a simpler alternative for monitoring how well interventions are working.
A new analysis of the TN10 trial reveals that teplizumab helps preserve the body's ability to make insulin in people with stage 2 type 1 diabetes, while untreated individuals experience a decline. The findings suggest that insulin clearance patterns may help predict who will progress more slowly toward diagnosis.
A Phase I trial of a plasmid-based therapy designed to train the immune system using insulin antigen shows promise in adults with established Type 1 diabetes. The treatment was well tolerated with no serious safety concerns.
Researchers discovered how a single change to insulin molecules in stressed pancreatic cells triggers and sustains immune attack, revealing a new piece of the type 1 diabetes puzzle.
Researchers are developing a new class of therapies designed to restore immune tolerance to the specific antigens that trigger Type 1 diabetes, rather than broadly suppressing the immune system. These approaches could preserve insulin-producing cells while maintaining overall immune protection.
A new study using continuous glucose monitors found that adding semaglutide or tirzepatide to insulin therapy helped reduce dangerous blood sugar swings during Ramadan. The findings suggest these medications could be a useful tool for people managing diabetes during religious fasting.
Glucose-responsive insulin-secreting stem cell-derived islet-like cells (SC-islets) are a promising source for beta cell replacement to treat type 1 diabetes (T1D).
Weekly GLP-1 medications, already approved for type 2 diabetes and weight management, are being studied as add-on treatments for people with type 1 diabetes who struggle to reach blood sugar targets with insulin alone.
Researchers modified insulin-producing cells to better survive after transplantation in diabetic mice by activating a natural immune-protection pathway. The findings suggest a possible direction for cell replacement therapy, though human testing is still years away.
New research maps the specific proteins the immune system attacks in Type 1 diabetes, opening doors to earlier diagnosis and precision treatments that could stop the disease before symptoms appear.
Autoimmune polyglandular syndrome type II (APS II) combines Type 1 diabetes with other autoimmune disorders, often causing delayed diagnosis. A recent case study reveals how recognizing this pattern can lead to lifesaving treatment.
Researchers have developed soluble antigen arrays that can precisely target the specific T cells involved in Type 1 diabetes. The early findings suggest these constructs could form the basis for more targeted treatments with fewer side effects.
Researchers are studying whether combining semaglutide and dapagliflozin with insulin can help adults with Type 1 diabetes reach better blood sugar targets while managing weight gain. The Phase 3 trial aims to determine if this triple-therapy approach is safe and effective.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by the destruction of insulin-producing pancreatic β-cells by autoreactive T cells.
AIM: To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Researchers developed an mRNA vaccine designed to train the immune system to tolerate insulin-producing cells, successfully delaying diabetes onset in a mouse model of the disease.
A new review finds that GLP-1 receptor agonists help people with Type 1 diabetes lose weight and use less insulin, yet their ability to protect the heart remains unproven.
As people with Type 1 diabetes live longer, researchers say the focus of treatment is shifting from simply lowering blood sugar to restoring the body's natural balance and reducing daily disease burden.
Researchers tested an unconventional strategy that uses a small islet transplant not to replace insulin production, but to teach the immune system to stop attacking the body's own beta cells. Early results show promise, though long-term durability remains to be determined.
A new review of research and patient perspectives reveals a gap between what adjunctive therapies currently offer and what the Type 1 diabetes community actually needs. Understanding these priorities could shape the future of treatment development.
A nationwide study finds that even with insulin therapy, significant numbers of people with Type 1 diabetes experience dangerous complications like severe low blood sugar and diabetic ketoacidosis.